It is quite bizarre that an industry that protects itself, claiming high prices for drugs, based on the assumed acceptance of taking on risk inherent in R&D is in fact so risk averse. Maybe the risk analysis in the pipe management isn’t so bad as Pharma makes it out to be! Thanks John for your post!
See on pharmamkting.blogspot.fr
